Observational studySleep & breathing = Schlaf & Atmung2026
Correlation between urinary 6-sulfatoxymelatonin and actigraphy data in a clinical population with sleep disorders: an observational study.
Observational study in Sleep & breathing = Schlaf & Atmung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCircadian rhythms (CR) regulate behavioral and physiological processes, including the sleep-wake cycle. Actigraphy provides objective behavioral data but is influenced by external factors, potentially masking endogenous circadian patterns. Urinary 6-sulfatoxymelatonin (aMT6s) offers a practical marker of endogenous CR in ecological settings. This study examined associations between aMT6s profiles and actigraphy-derived sleep parameters in a clinical population with sleep disturbances.
methodsA retrospective analysis was conducted on 69 adult patients assessed in 2023 at the University Hospital of Besançon. Of these, 40 exhibited significant aMT6s rhythmicity and were included in final analyses. Actigraphy data included sleep onset, midpoint, offset, and sleep architecture metrics. aMT6s was collected in 3-hour intervals over 24 h under naturalistic conditions. Cosinor analysis was used to determine aMT6s acrophase, amplitude, and mesor. Pearson correlations were calculated to assess associations between aMT6s and actigraphy measures under both fixed and free sleep schedules.
resultsaMT6s acrophase showed moderate correlations with sleep onset (r = 0.46), midpoint (r = 0.61), and offset (r = 0.63). Stronger correlations were observed under fixed schedules. aMT6s amplitude and mesor demonstrated weaker associations with sleep timing and latency.
conclusionThe moderate, context-dependent correlations underscore that these tools are not redundant but capture distinct aspects of sleep-wake regulation. In a heterogeneous clinical population, this supports a stratified diagnostic approach, using actigraphy as a first-line screening tool and reserving aMT6s assessment for complex cases. This multimodal strategy can refine evaluation and guide personalized chronobiological interventions. Prospective studies are needed to validate the implementation criteria for this stepped-care model in clinical practice.
Indexed as
Identifiers
42207368What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.